San Diego - (NewMediaWire) - March 8, 2021 - SigynTherapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused onthe treatment of life-threatening inflammatory conditions precipitated byCytokine Storm Syndrome (the Cytokine Storm), today announced that Jim Joyce,its Chairman and Chief Executive Officer, will present at the H.C. WainwrightGlobal Life Sciences Conference that will take place virtually tomorrow March9th and Wednesday March 10, 2021.
To register for the event,please visit: https://my.ct.events/register.aspx?meid=fc99b171-2574-4558-bda3-3ba391b6e555&rpid=75ab29bf-f328-45e8-9008-d5e88edeea28
Mr. Joyce’s presentation will beavailable beginning March 9, 2021 at 7:00am EST and can also be accessed at theinvestor relations section of the Sigyn Therapeutics website at www.sigyntherapeutics.com
About Sigyn Therapeutics
Sigyn Therapeutics™ is adevelopment-stage therapeutic technology company headquartered in San Diego,California USA. Our focus is directed toward a significant unmet need in globalhealth; the treatment of life-threatening inflammatory conditions that areprecipitated by Cytokine Storm Syndrome and not addressed with an approvedtherapy. Our mission is to save lives.
Sigyn Therapy™ is a novel bloodpurification technology designed to mitigate cytokine storm syndrome throughthe broad-spectrum depletion of inflammatory targets from the bloodstream.Cytokine storm syndrome is the hallmark of sepsis, which is the most commoncause of in-hospital deaths and claims more lives each year than all forms ofcancer combined. Virus induced cytokine storm (VICS) is associated with highmortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Othertherapeutic opportunities include, but are not limited to bacteria inducedcytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acuteforms of liver failure, such as hepatic encephalopathy.
To learn more, visit www.SigynTherapeutics.com
Cautionary Note RegardingForward-Looking Statements
This press release containsforward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involvesubstantial risks and uncertainties. All statements contained in this pressrelease are forward-looking statements within the meaning of The PrivateSecurities Litigation Reform Act of 1995. The words “could,” “will,” “plan,”“intend,” “anticipate,” “approximate,” “expect,” “potential,” or the negativeof these terms or other similar expressions are intended to identifyforward-looking statements, although not all forward-looking statements containthese identifying words. These forward-looking statements include, amongothers, statements about Sigyn’s future financial performance, the impact ofmanagement changes, any proposed organizational restructuring, results ofoperations, capital resources to fund operations; statements about Sigyn’sexpectations regarding the capitalization, resources and ownership structure ofthe combined company; statements about the potential benefits of thetransaction; the expected completion and timing of the transaction and otherinformation relating to the transaction; and any other statements other thanstatements of historical fact. Actual results or events could differ materiallyfrom the plans, intentions and expectations disclosed in the forward-lookingstatements that Sigyn makes due to a number of important factors, including (i)the risk that the transaction may not be completed in a timely manner or atall, which may adversely affect Sigyn’s business and the price of the commonstock of Sigyn, (ii) the failure to satisfy of the conditions to theconsummation of the transaction, (iii) the occurrence of any event, change or othercircumstance that could give rise to the termination of the merger agreement,(iv) risks related to the ability to realize the anticipated benefits of thetransaction, including the risk that the businesses will not be integratedsuccessfully, (v) the effect of the announcement or pendency of the transactionon Sigyn’s business relationships, operating results and business generally,(vi) risks that the proposed transaction disrupts current plans and operations,(vii) risks related to the combined entity’s ability to up-list to a nationalsecurities exchange, (viii) risks related to the combined entity’s access toexisting capital and fundraising prospects to fund its ongoing operations, (ix)risks related to diverting management’s attention from Sigyn’s ongoing businessoperations, (x) other business effects, including the effects of industry,market, economic, political or regulatory conditions, future exchange andinterest rates, and changes in tax and other laws, regulations, rates andpolicies, and (xi) risks related to an inability to manufacture Sigyn Therapy,risks related to the clinical advancement of Sigyn Therapy with regulatoryagencies, and no assurance that Sigyn Therapy will be proven to be a safe andefficacious treatment for any condition. The forward-looking statements in thispress release represent Sigyn’s views as of the date of this press release.Sigyn anticipates that subsequent events and developments may cause its viewsto change. However, while it may elect to update these forward-lookingstatements at some point in the future, it specifically disclaims anyobligation to do so. You should, therefore, not rely on these forward-lookingstatements as representing Sigyn’s views as of any date subsequent to the dateof this press release.
Contact Sigyn Therapeutics,Inc.
Jim Joyce
Chairman, CEO
(619) 368-2000
jj@sigyntherapeutics.com